Lidocaine Egis

Lidocaine, the active ingredient in Lidocaine Egis, is a local anesthetic presented as a sterile solution for epidural, infiltration, intravenous and peripheral nerve block use. It provides reversible loss of sensation for minor surgical procedures, labor analgesia, cardiac arrhythmia management and peripheral nerve block in adult patients.

GNH USA supplies Lidocaine Egis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with adherence to EU quality standards and batch‑release procedures through a robust logistics network.

Lidocaine is a local anesthetic used to block nerve conduction in various clinical settings.

Minor surgical procedures: provides reversible loss of sensation in the targeted area, facilitating painless incision and excision. Epidural analgesia: delivers continuous pain relief during labor or postoperative recovery by numbing spinal nerve roots. Intravenous antiarrhythmic therapy: stabilizes cardiac rhythm in selected ventricular and supraventricular arrhythmias. Peripheral nerve block: produces localized anesthesia for limb surgeries and diagnostic procedures.

Lidocaine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Tingling or numbness at the injection site - Mild hypotension - Dizziness or light‑headedness - Nausea or vomiting - Local irritation or erythema - Transient metallic taste

Serious or Rare Side Effects: - Methemoglobinemia - Seizures or convulsions - Cardiac arrest or severe arrhythmias - Anaphylactic or severe allergic reaction - Respiratory depression - Systemic toxic reaction with CNS and cardiovascular collapse

When using Lidocaine, clinicians should observe several safety measures to minimise risk.

Assess allergy: verify no known hypersensitivity to amide‑type local anesthetics. Monitor cardiac function: observe for arrhythmias during intravenous administration. Use lowest effective concentration: reduce risk of systemic toxicity. Avoid concurrent CNS depressants: may potentiate sedation and respiratory depression. Pregnancy and lactation: evaluate risk‑benefit before use. Store below 25°C: keep in original container, protect from moisture and light.

Lidocaine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): additive cardiotoxicity. - Beta‑adrenergic blockers: may enhance bradycardia. - General anesthetics (e.g., propofol): increased CNS depression. - Monoamine oxidase inhibitors: risk of hypertension. - Other local anesthetics: cumulative toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may increase plasma levels. - Diuretics: may alter plasma protein binding. - Hypoglycemic agents: can mask symptoms of hypoglycemia. - Alcohol: enhances CNS effects. - Nonsteroidal anti‑inflammatory drugs: may increase bleeding risk.